Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study

Objectives: To evaluate the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by Enterobacteriaceae and Pseudomonas aeruginosa in one French region. Methods: During 2001–2002, all the non-duplicate isolates of P. aeruginosa resistant to ceftazidime and of Enterobacteriaceae...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 2004-09, Vol.54 (3), p.634-639
Hauptverfasser: De Champs, C., Chanal, C., Sirot, D., Baraduc, R., Romaszko, J. P., Bonnet, R., Plaidy, A., Boyer, M., Carroy, E., Gbadamassi, M. C., Laluque, S., Oules, O., Poupart, M. C., Villemain, M., Sirot, J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 639
container_issue 3
container_start_page 634
container_title Journal of antimicrobial chemotherapy
container_volume 54
creator De Champs, C.
Chanal, C.
Sirot, D.
Baraduc, R.
Romaszko, J. P.
Bonnet, R.
Plaidy, A.
Boyer, M.
Carroy, E.
Gbadamassi, M. C.
Laluque, S.
Oules, O.
Poupart, M. C.
Villemain, M.
Sirot, J.
description Objectives: To evaluate the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by Enterobacteriaceae and Pseudomonas aeruginosa in one French region. Methods: During 2001–2002, all the non-duplicate isolates of P. aeruginosa resistant to ceftazidime and of Enterobacteriaceae intermediate or resistant to ceftazidime and/or cefotaxime and/or aminoglycosides with an AAC(6′) I phenotype were collected in nine hospitals of the area. ESBL isoelectric points were determined, bla genes were amplified and sequenced and epidemic isolates were genotyped with ERIC2-PCR. Results: ESBLs were observed in 297 Enterobacteriaceae (0.8%). The most frequent were TEM-3 like (n=152; 51.2%) and TEM-24 (n=115; 38.7%). Four new enzymes were observed, TEM-112 (pI 5.4), TEM-113 (pI 6.3), TEM-114 (pI 5.9) and TEM-126 (pI 5.4). Other TEMs were TEM-8, TEM-12, TEM-16, TEM-19, TEM-20, TEM-21, TEM-29 and TEM-71. The other ESBLs were SHV-4, SHV-5 and SHV-12, CTX-M-1, CTX-M-3, CTX-M-14 and CTX-M-15. In 37 P. aeruginosa (0.7%) only one ESBL was observed, PER-1. Five epidemic strains were detected, Serratia marcescens TEM-3 and four observed in several hospitals, Enterobacter aerogenes TEM-24, Citrobacter koseri TEM-3, Proteus mirabilis TEM-3 and P. aeruginosa PER-1. Conclusion: ESBL frequency was lower than in 1998, and CTX-M-type frequency higher (2.1% of ESBLs in 2001, 4.9% in 2002). This long-term survey detected new sporadic enzymes (TEM-112, TEM-113, TEM-114 and TEM-126) and interhospital epidemic strains while avoiding any overestimation of ESBL frequency that may otherwise have occurred because of acute epidemics.
doi_str_mv 10.1093/jac/dkh395
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66816902</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17795519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-5577152b0646413120111cf5050cefd5d6c2fa766f114d9486da6939e5f70cfe3</originalsourceid><addsrcrecordid>eNqFkcFuEzEQhi0EomnhwgMgX-BQsdSzXtvr3qJAKFIlkAAJ9WK59phsu9kE24u6Z96IB-GZcEhEj5zmMN_8M__8hDwD9hqY5mc31p352xXX4gGZQSNZVTMND8mMcSYq1Qh-RI5TumGMSSHbx-QIRN3WdcNm5Ocy4vcRBzdRO3jqux8YU5cnugl00duU6JziXcbBo6_SFl2O45r-_lX11mW7tgkT7Qa62qRtl22fdnN5hXQ-FqFvA76iy2gHh-fU0ppOaCPdxs1fobKKpjz66Ql5FMooPj3UE_Jl-fbz4qK6_PDu_WJ-WbkG2lwJoVQ5_JrJRjbAoWYA4IJggjkMXnjp6mCVlAGg8bpppbdSc40iKOYC8hPycq9bLiieUzbrLjnsezvgZkxGyhakZvV_QVBKCwG6gKd70BVPKWIw29itbZwMMLPLxpRszD6bAj8_qI7Xa_T36CGMArw4ADY524fd47p0z0nQWksoXLXnupTx7l_fxlsjFVfCXHy9Mp-4UvJN_dFc8T8IrKfL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17795519</pqid></control><display><type>article</type><title>Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>De Champs, C. ; Chanal, C. ; Sirot, D. ; Baraduc, R. ; Romaszko, J. P. ; Bonnet, R. ; Plaidy, A. ; Boyer, M. ; Carroy, E. ; Gbadamassi, M. C. ; Laluque, S. ; Oules, O. ; Poupart, M. C. ; Villemain, M. ; Sirot, J.</creator><creatorcontrib>De Champs, C. ; Chanal, C. ; Sirot, D. ; Baraduc, R. ; Romaszko, J. P. ; Bonnet, R. ; Plaidy, A. ; Boyer, M. ; Carroy, E. ; Gbadamassi, M. C. ; Laluque, S. ; Oules, O. ; Poupart, M. C. ; Villemain, M. ; Sirot, J.</creatorcontrib><description>Objectives: To evaluate the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by Enterobacteriaceae and Pseudomonas aeruginosa in one French region. Methods: During 2001–2002, all the non-duplicate isolates of P. aeruginosa resistant to ceftazidime and of Enterobacteriaceae intermediate or resistant to ceftazidime and/or cefotaxime and/or aminoglycosides with an AAC(6′) I phenotype were collected in nine hospitals of the area. ESBL isoelectric points were determined, bla genes were amplified and sequenced and epidemic isolates were genotyped with ERIC2-PCR. Results: ESBLs were observed in 297 Enterobacteriaceae (0.8%). The most frequent were TEM-3 like (n=152; 51.2%) and TEM-24 (n=115; 38.7%). Four new enzymes were observed, TEM-112 (pI 5.4), TEM-113 (pI 6.3), TEM-114 (pI 5.9) and TEM-126 (pI 5.4). Other TEMs were TEM-8, TEM-12, TEM-16, TEM-19, TEM-20, TEM-21, TEM-29 and TEM-71. The other ESBLs were SHV-4, SHV-5 and SHV-12, CTX-M-1, CTX-M-3, CTX-M-14 and CTX-M-15. In 37 P. aeruginosa (0.7%) only one ESBL was observed, PER-1. Five epidemic strains were detected, Serratia marcescens TEM-3 and four observed in several hospitals, Enterobacter aerogenes TEM-24, Citrobacter koseri TEM-3, Proteus mirabilis TEM-3 and P. aeruginosa PER-1. Conclusion: ESBL frequency was lower than in 1998, and CTX-M-type frequency higher (2.1% of ESBLs in 2001, 4.9% in 2002). This long-term survey detected new sporadic enzymes (TEM-112, TEM-113, TEM-114 and TEM-126) and interhospital epidemic strains while avoiding any overestimation of ESBL frequency that may otherwise have occurred because of acute epidemics.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkh395</identifier><identifier>PMID: 15282240</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Amino Acid Substitution ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; beta-Lactamases - genetics ; Biological and medical sciences ; Citrobacter koseri ; Cloning, Molecular ; Cross Infection - epidemiology ; Cross Infection - microbiology ; DNA Primers ; Enterobacter aerogenes ; Enterobacteriaceae ; Enterobacteriaceae - drug effects ; Enterobacteriaceae - enzymology ; Enterobacteriaceae - genetics ; epidemiology ; ESBLs ; France - epidemiology ; Gene Frequency ; Humans ; Isoelectric Focusing ; Medical sciences ; Pharmacology. Drug treatments ; Population Surveillance ; Prospective Studies ; Proteus mirabilis ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas aeruginosa - enzymology ; Pseudomonas aeruginosa - genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Serratia marcescens</subject><ispartof>Journal of antimicrobial chemotherapy, 2004-09, Vol.54 (3), p.634-639</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-5577152b0646413120111cf5050cefd5d6c2fa766f114d9486da6939e5f70cfe3</citedby><cites>FETCH-LOGICAL-c418t-5577152b0646413120111cf5050cefd5d6c2fa766f114d9486da6939e5f70cfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16199961$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15282240$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>De Champs, C.</creatorcontrib><creatorcontrib>Chanal, C.</creatorcontrib><creatorcontrib>Sirot, D.</creatorcontrib><creatorcontrib>Baraduc, R.</creatorcontrib><creatorcontrib>Romaszko, J. P.</creatorcontrib><creatorcontrib>Bonnet, R.</creatorcontrib><creatorcontrib>Plaidy, A.</creatorcontrib><creatorcontrib>Boyer, M.</creatorcontrib><creatorcontrib>Carroy, E.</creatorcontrib><creatorcontrib>Gbadamassi, M. C.</creatorcontrib><creatorcontrib>Laluque, S.</creatorcontrib><creatorcontrib>Oules, O.</creatorcontrib><creatorcontrib>Poupart, M. C.</creatorcontrib><creatorcontrib>Villemain, M.</creatorcontrib><creatorcontrib>Sirot, J.</creatorcontrib><title>Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>Objectives: To evaluate the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by Enterobacteriaceae and Pseudomonas aeruginosa in one French region. Methods: During 2001–2002, all the non-duplicate isolates of P. aeruginosa resistant to ceftazidime and of Enterobacteriaceae intermediate or resistant to ceftazidime and/or cefotaxime and/or aminoglycosides with an AAC(6′) I phenotype were collected in nine hospitals of the area. ESBL isoelectric points were determined, bla genes were amplified and sequenced and epidemic isolates were genotyped with ERIC2-PCR. Results: ESBLs were observed in 297 Enterobacteriaceae (0.8%). The most frequent were TEM-3 like (n=152; 51.2%) and TEM-24 (n=115; 38.7%). Four new enzymes were observed, TEM-112 (pI 5.4), TEM-113 (pI 6.3), TEM-114 (pI 5.9) and TEM-126 (pI 5.4). Other TEMs were TEM-8, TEM-12, TEM-16, TEM-19, TEM-20, TEM-21, TEM-29 and TEM-71. The other ESBLs were SHV-4, SHV-5 and SHV-12, CTX-M-1, CTX-M-3, CTX-M-14 and CTX-M-15. In 37 P. aeruginosa (0.7%) only one ESBL was observed, PER-1. Five epidemic strains were detected, Serratia marcescens TEM-3 and four observed in several hospitals, Enterobacter aerogenes TEM-24, Citrobacter koseri TEM-3, Proteus mirabilis TEM-3 and P. aeruginosa PER-1. Conclusion: ESBL frequency was lower than in 1998, and CTX-M-type frequency higher (2.1% of ESBLs in 2001, 4.9% in 2002). This long-term survey detected new sporadic enzymes (TEM-112, TEM-113, TEM-114 and TEM-126) and interhospital epidemic strains while avoiding any overestimation of ESBL frequency that may otherwise have occurred because of acute epidemics.</description><subject>Amino Acid Substitution</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>beta-Lactamases - genetics</subject><subject>Biological and medical sciences</subject><subject>Citrobacter koseri</subject><subject>Cloning, Molecular</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - microbiology</subject><subject>DNA Primers</subject><subject>Enterobacter aerogenes</subject><subject>Enterobacteriaceae</subject><subject>Enterobacteriaceae - drug effects</subject><subject>Enterobacteriaceae - enzymology</subject><subject>Enterobacteriaceae - genetics</subject><subject>epidemiology</subject><subject>ESBLs</subject><subject>France - epidemiology</subject><subject>Gene Frequency</subject><subject>Humans</subject><subject>Isoelectric Focusing</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Population Surveillance</subject><subject>Prospective Studies</subject><subject>Proteus mirabilis</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas aeruginosa - enzymology</subject><subject>Pseudomonas aeruginosa - genetics</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Serratia marcescens</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFuEzEQhi0EomnhwgMgX-BQsdSzXtvr3qJAKFIlkAAJ9WK59phsu9kE24u6Z96IB-GZcEhEj5zmMN_8M__8hDwD9hqY5mc31p352xXX4gGZQSNZVTMND8mMcSYq1Qh-RI5TumGMSSHbx-QIRN3WdcNm5Ocy4vcRBzdRO3jqux8YU5cnugl00duU6JziXcbBo6_SFl2O45r-_lX11mW7tgkT7Qa62qRtl22fdnN5hXQ-FqFvA76iy2gHh-fU0ppOaCPdxs1fobKKpjz66Ql5FMooPj3UE_Jl-fbz4qK6_PDu_WJ-WbkG2lwJoVQ5_JrJRjbAoWYA4IJggjkMXnjp6mCVlAGg8bpppbdSc40iKOYC8hPycq9bLiieUzbrLjnsezvgZkxGyhakZvV_QVBKCwG6gKd70BVPKWIw29itbZwMMLPLxpRszD6bAj8_qI7Xa_T36CGMArw4ADY524fd47p0z0nQWksoXLXnupTx7l_fxlsjFVfCXHy9Mp-4UvJN_dFc8T8IrKfL</recordid><startdate>20040901</startdate><enddate>20040901</enddate><creator>De Champs, C.</creator><creator>Chanal, C.</creator><creator>Sirot, D.</creator><creator>Baraduc, R.</creator><creator>Romaszko, J. P.</creator><creator>Bonnet, R.</creator><creator>Plaidy, A.</creator><creator>Boyer, M.</creator><creator>Carroy, E.</creator><creator>Gbadamassi, M. C.</creator><creator>Laluque, S.</creator><creator>Oules, O.</creator><creator>Poupart, M. C.</creator><creator>Villemain, M.</creator><creator>Sirot, J.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20040901</creationdate><title>Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study</title><author>De Champs, C. ; Chanal, C. ; Sirot, D. ; Baraduc, R. ; Romaszko, J. P. ; Bonnet, R. ; Plaidy, A. ; Boyer, M. ; Carroy, E. ; Gbadamassi, M. C. ; Laluque, S. ; Oules, O. ; Poupart, M. C. ; Villemain, M. ; Sirot, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-5577152b0646413120111cf5050cefd5d6c2fa766f114d9486da6939e5f70cfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Amino Acid Substitution</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>beta-Lactamases - genetics</topic><topic>Biological and medical sciences</topic><topic>Citrobacter koseri</topic><topic>Cloning, Molecular</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - microbiology</topic><topic>DNA Primers</topic><topic>Enterobacter aerogenes</topic><topic>Enterobacteriaceae</topic><topic>Enterobacteriaceae - drug effects</topic><topic>Enterobacteriaceae - enzymology</topic><topic>Enterobacteriaceae - genetics</topic><topic>epidemiology</topic><topic>ESBLs</topic><topic>France - epidemiology</topic><topic>Gene Frequency</topic><topic>Humans</topic><topic>Isoelectric Focusing</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Population Surveillance</topic><topic>Prospective Studies</topic><topic>Proteus mirabilis</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas aeruginosa - enzymology</topic><topic>Pseudomonas aeruginosa - genetics</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Serratia marcescens</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Champs, C.</creatorcontrib><creatorcontrib>Chanal, C.</creatorcontrib><creatorcontrib>Sirot, D.</creatorcontrib><creatorcontrib>Baraduc, R.</creatorcontrib><creatorcontrib>Romaszko, J. P.</creatorcontrib><creatorcontrib>Bonnet, R.</creatorcontrib><creatorcontrib>Plaidy, A.</creatorcontrib><creatorcontrib>Boyer, M.</creatorcontrib><creatorcontrib>Carroy, E.</creatorcontrib><creatorcontrib>Gbadamassi, M. C.</creatorcontrib><creatorcontrib>Laluque, S.</creatorcontrib><creatorcontrib>Oules, O.</creatorcontrib><creatorcontrib>Poupart, M. C.</creatorcontrib><creatorcontrib>Villemain, M.</creatorcontrib><creatorcontrib>Sirot, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Champs, C.</au><au>Chanal, C.</au><au>Sirot, D.</au><au>Baraduc, R.</au><au>Romaszko, J. P.</au><au>Bonnet, R.</au><au>Plaidy, A.</au><au>Boyer, M.</au><au>Carroy, E.</au><au>Gbadamassi, M. C.</au><au>Laluque, S.</au><au>Oules, O.</au><au>Poupart, M. C.</au><au>Villemain, M.</au><au>Sirot, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2004-09-01</date><risdate>2004</risdate><volume>54</volume><issue>3</issue><spage>634</spage><epage>639</epage><pages>634-639</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives: To evaluate the frequency and diversity of extended-spectrum β-lactamases (ESBLs) produced by Enterobacteriaceae and Pseudomonas aeruginosa in one French region. Methods: During 2001–2002, all the non-duplicate isolates of P. aeruginosa resistant to ceftazidime and of Enterobacteriaceae intermediate or resistant to ceftazidime and/or cefotaxime and/or aminoglycosides with an AAC(6′) I phenotype were collected in nine hospitals of the area. ESBL isoelectric points were determined, bla genes were amplified and sequenced and epidemic isolates were genotyped with ERIC2-PCR. Results: ESBLs were observed in 297 Enterobacteriaceae (0.8%). The most frequent were TEM-3 like (n=152; 51.2%) and TEM-24 (n=115; 38.7%). Four new enzymes were observed, TEM-112 (pI 5.4), TEM-113 (pI 6.3), TEM-114 (pI 5.9) and TEM-126 (pI 5.4). Other TEMs were TEM-8, TEM-12, TEM-16, TEM-19, TEM-20, TEM-21, TEM-29 and TEM-71. The other ESBLs were SHV-4, SHV-5 and SHV-12, CTX-M-1, CTX-M-3, CTX-M-14 and CTX-M-15. In 37 P. aeruginosa (0.7%) only one ESBL was observed, PER-1. Five epidemic strains were detected, Serratia marcescens TEM-3 and four observed in several hospitals, Enterobacter aerogenes TEM-24, Citrobacter koseri TEM-3, Proteus mirabilis TEM-3 and P. aeruginosa PER-1. Conclusion: ESBL frequency was lower than in 1998, and CTX-M-type frequency higher (2.1% of ESBLs in 2001, 4.9% in 2002). This long-term survey detected new sporadic enzymes (TEM-112, TEM-113, TEM-114 and TEM-126) and interhospital epidemic strains while avoiding any overestimation of ESBL frequency that may otherwise have occurred because of acute epidemics.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15282240</pmid><doi>10.1093/jac/dkh395</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2004-09, Vol.54 (3), p.634-639
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_66816902
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry
subjects Amino Acid Substitution
Antibiotics. Antiinfectious agents. Antiparasitic agents
beta-Lactamases - genetics
Biological and medical sciences
Citrobacter koseri
Cloning, Molecular
Cross Infection - epidemiology
Cross Infection - microbiology
DNA Primers
Enterobacter aerogenes
Enterobacteriaceae
Enterobacteriaceae - drug effects
Enterobacteriaceae - enzymology
Enterobacteriaceae - genetics
epidemiology
ESBLs
France - epidemiology
Gene Frequency
Humans
Isoelectric Focusing
Medical sciences
Pharmacology. Drug treatments
Population Surveillance
Prospective Studies
Proteus mirabilis
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Pseudomonas aeruginosa - enzymology
Pseudomonas aeruginosa - genetics
Reverse Transcriptase Polymerase Chain Reaction
Serratia marcescens
title Frequency and diversity of Class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A21%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20and%20diversity%20of%20Class%20A%20extended-spectrum%20%CE%B2-lactamases%20in%20hospitals%20of%20the%20Auvergne,%20France:%20a%202%20year%20prospective%20study&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=De%20Champs,%20C.&rft.date=2004-09-01&rft.volume=54&rft.issue=3&rft.spage=634&rft.epage=639&rft.pages=634-639&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkh395&rft_dat=%3Cproquest_cross%3E17795519%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17795519&rft_id=info:pmid/15282240&rfr_iscdi=true